E Lopci1, I Santi1, E Derenzini2, C Fonti1, G Savelli3, F Bertagna3, M Bellò4, B Botto5, D Huglo6, F Morschhauser6, P Zinzani2, S Fanti7. 1. PET Unit, Nuclear Medicine Department, University Hospital S. Orsola-Malpighi, Bologna. 2. Department of Hematology, 'L. Seragnoli' Institution, University Hospital S. Orsola-Malpighi, Bologna. 3. Department of Nuclear Medicine, Spedali Civili, Brescia. 4. Department of Nuclear Medicine. 5. Department of Hematology, University Hospital San Giovanni Battista, Torino, Italy. 6. Department of Nuclear Medicine, University Hospital Claude Huriez, Lille, France. 7. PET Unit, Nuclear Medicine Department, University Hospital S. Orsola-Malpighi, Bologna. Electronic address: stefano.fanti@aosp.bo.it.
Abstract
BACKGROUND: The aim of this study is the 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) evaluation following radioimmunotherapy (RIT) with ibritumomab tiuxetan Y 90 in patients with non-Hodgkin's follicular lymphoma (FL). MATERIALS AND METHODS: We retrospectively analyzed data from 59 relapsed or refractory FL patients treated with ibritumomab tiuxetan Y 90 in four different PET centers who had a PET scan carried out before and after RIT. Possible predictive factors of progression-free survival (PFS) were studied through univariate and multivariate analysis. RESULTS: The post-RIT PET documented 45.8% complete responders (CR), 25.4% partial responders (PR) and 28.8% nonresponders [stable disease + progressive disease], with an overall survival of 71.2% (range 59.5%-90.9%). With a median follow-up period of 23 months, the univariate analysis documented a statistically significant relation between disease extent before RIT and response to treatment with respect to PFS (P = 0.015), while all the other prognostic factors showed no significant correlation. When carrying out the multivariate analysis, post-RIT PET resulted as the lonely independent predictor of PFS (P < 0.00001). CONCLUSIONS: RIT is an effective therapy in FL patients, as confirmed in our study too. Disease extension before treatment and response to RIT, as assessed by FDG-PET, result as main predictors of PFS, with the post-RIT PET result being the only independent predictive factor.
BACKGROUND: The aim of this study is the 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) evaluation following radioimmunotherapy (RIT) with ibritumomab tiuxetan Y 90 in patients with non-Hodgkin's follicular lymphoma (FL). MATERIALS AND METHODS: We retrospectively analyzed data from 59 relapsed or refractory FL patients treated with ibritumomab tiuxetan Y 90 in four different PET centers who had a PET scan carried out before and after RIT. Possible predictive factors of progression-free survival (PFS) were studied through univariate and multivariate analysis. RESULTS: The post-RIT PET documented 45.8% complete responders (CR), 25.4% partial responders (PR) and 28.8% nonresponders [stable disease + progressive disease], with an overall survival of 71.2% (range 59.5%-90.9%). With a median follow-up period of 23 months, the univariate analysis documented a statistically significant relation between disease extent before RIT and response to treatment with respect to PFS (P = 0.015), while all the other prognostic factors showed no significant correlation. When carrying out the multivariate analysis, post-RIT PET resulted as the lonely independent predictor of PFS (P < 0.00001). CONCLUSIONS: RIT is an effective therapy in FL patients, as confirmed in our study too. Disease extension before treatment and response to RIT, as assessed by FDG-PET, result as main predictors of PFS, with the post-RIT PET result being the only independent predictive factor.
Authors: Francesco Pisani; Carlo Ludovico Maini; Rosa Sciuto; Laura Dessanti; Mariella D'Andrea; Daniela Assisi; Maria Concetta Petti Journal: J Exp Clin Cancer Res Date: 2011-02-08
Authors: Francesco Pisani; Rosa Sciuto; Maria Laura Dessanti; Diana Giannarelli; Ramy Kayal; Sandra Rea; Francesco Marchesi; Mirella Marino Journal: Exp Hematol Oncol Date: 2015-06-24